Skip to content

Study · Non-randomized trial · n = 52 · 1996

7 results

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours.

Arnold R, Trautmann ME, Creutzfeldt W, Benning R, Benning M, Neuhaus C, Jürgensen R, Stein K, Schäfer H, Bruns C, Dennler HJ

Gut1 Mar 1996Cited by 216 (Europe PMC)

PMID8675099 (opens in a new tab)PMCIDPMC1383075 (opens in a new tab)DOI10.1136/gut.38.3.430 (opens in a new tab)PepBankPUB-08675099
Source linkPubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with progressive metastatic endocrine GEP tumours given octreotide, stabilisation of tumour growth lasting at least three months occurred in 19 patients (36.5%).

    In plain wordsIn patients with progressive endocrine GEP tumours on octreotide, tumour growth stabilised for at least three months in 36.5%.

    Peptide
    Octreotide
    Outcome
    Not applicableTumour stabilisation
    Study

    n = 52

    Outcome group
    Tumor growth · Cancer
    Studied dose
    200 micrograms thrice dailyAs given in this study (human).

    Measurements

    Patients with stabilisation of tumour growth for at least three months
    19 patients
    patients with CT-confirmed progression
    Patients with stabilisation of tumour growth for at least three months
    36.5%
    patients with CT-confirmed progression

    Source sentences

    Summary
    Nineteen patients (36.5%) with computed tomography confirmed tumour progression experienced stabilisation of tumour growth lasting for at least three months.
    1 context sentence
    Summary · context
    The prospective German Sandostatin multicentre phase II trial investigated the effects of 200 micrograms octreotide thrice daily for one year on tumour growth and endocrine abnormalities in 103 patients.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with progressing endocrine GEP tumours, octreotide dose escalation did not alter progression except for one patient who achieved stable disease.

    In plain wordsIn patients with progressing endocrine GEP tumours, higher-dose octreotide did not alter progression except for one patient who achieved stable disease.

    Peptide
    Octreotide
    Outcome
    MixedProgression after dose escalation
    Study

    n = 28

    Comparator
    200 micrograms thrice daily
    Outcome group
    Tumor growth · Cancer
    Studied dose
    500 micrograms thrice dailyAs given in this study (human).

    Measurements

    Patients whose progression changed to stable disease after dose increase
    1 patient
    28 patients escalated to 500 micrograms thrice daily

    Source sentences

    Summary
    Increase of octreotide dose to 500 micrograms thrice daily did not influence progression seen during the lower dose with the exception of one patient in whom tumour progression changed to stable disease.
    2 context sentences
    Summary · context
    In 28 of those with tumour progression during 200 micrograms thrice daily octreotide dose was increased to 500 micrograms thrice daily.
    Summary · context
    The prospective German Sandostatin multicentre phase II trial investigated the effects of 200 micrograms octreotide thrice daily for one year on tumour growth and endocrine abnormalities in 103 patients.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with stable disease before octreotide, stable disease continued in 53.8% over 12 months.

    In plain wordsIn patients with stable disease before octreotide, 53.8% remained stable over 12 months.

    Peptide
    Octreotide
    Outcome
    Not applicableStable disease continuation
    Study

    n = 13

    Outcome group
    Tumor growth · Cancer
    Studied dose
    200 micrograms thrice dailyAs given in this study (human).

    Measurements

    Patients with stable disease continued over 12 months
    53.8%
    subgroup with stable disease before octreotide

    Source sentences

    Summary
    In the subgroup with stable disease before octreotide, stable disease continued in 53.8% of patients over 12 months.
    1 context sentence
    Summary · context
    The prospective German Sandostatin multicentre phase II trial investigated the effects of 200 micrograms octreotide thrice daily for one year on tumour growth and endocrine abnormalities in 103 patients.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with metastatic endocrine GEP tumours receiving octreotide, median stable disease duration was 18 months.

    In plain wordsIn patients with endocrine GEP tumours receiving octreotide, stable disease lasted a median of 18 months.

    Peptide
    Octreotide
    Outcome
    Not applicableStable disease duration
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    200 micrograms thrice dailyAs given in this study (human).

    Measurements

    Median duration of stable disease
    18 months
    patients with stabilisation

    Source sentences

    Summary
    Median duration of stable disease was 18 months.
    1 context sentence
    Summary · context
    The prospective German Sandostatin multicentre phase II trial investigated the effects of 200 micrograms octreotide thrice daily for one year on tumour growth and endocrine abnormalities in 103 patients.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients receiving octreotide, stable disease continued in 12 patients at month 12, nine after 24 months, and five after 36 months.

    In plain wordsIn patients receiving octreotide, stable disease continued in 12 patients at month 12, nine after 24 months, and five after 36 months.

    Peptide
    Octreotide
    Outcome
    Not applicableContinued stable disease
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    200 micrograms thrice dailyAs given in this study (human).

    Measurements

    Patients with continued stable disease
    12 patients
    month 12
    Patients with continued stable disease
    9 patients
    after 24 months
    Patients with continued stable disease
    5 patients
    after 36 months

    Source sentences

    Summary
    At month 12, stable disease continued in 12 patients, declined after 24 months to nine patients, and after 36 months to five patients.
    1 context sentence
    Summary · context
    The prospective German Sandostatin multicentre phase II trial investigated the effects of 200 micrograms octreotide thrice daily for one year on tumour growth and endocrine abnormalities in 103 patients.
  6. 06HumanNon-randomized trialEfficacy outcome

    In patients with metastatic endocrine GEP tumours receiving octreotide, no tumour regression occurred in any subgroup.

    In plain wordsIn patients with endocrine GEP tumours receiving octreotide, no subgroup showed tumour regression.

    Peptide
    Octreotide
    Outcome
    Not applicableTumour regression
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    200 micrograms thrice dailyAs given in this study (human).

    Source sentences

    Summary
    Tumour regression has not been seen in this or other subgroups.
    1 context sentence
    Summary · context
    The prospective German Sandostatin multicentre phase II trial investigated the effects of 200 micrograms octreotide thrice daily for one year on tumour growth and endocrine abnormalities in 103 patients.
  7. 07HumanObservational studyEfficacy outcome

    In octreotide-treated patients with endocrine GEP tumours, tumour size response showed no association with patient characteristics.

    In plain wordsIn octreotide-treated patients with endocrine GEP tumours, tumour size response was not linked to patient characteristics.

    Peptide
    Octreotide
    Outcome
    No significant changeResponse association with patient characteristics
    Study

    n: not reported in source

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No association of tumour size response and patients' characteristics could be detected.
    1 context sentence
    Summary · context
    The prospective German Sandostatin multicentre phase II trial investigated the effects of 200 micrograms octreotide thrice daily for one year on tumour growth and endocrine abnormalities in 103 patients.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.